CLX Maintained at Buy by Jefferies, April 2026

Jefferies maintained its Buy rating on Clorox (CLX) on April 21, 2026, though the firm adjusted its price target downward. The analyst firm lowered its target to $139 from $151, reflecting a more cautious near-term outlook. Despite the target reduction, the Clorox analyst rating remains constructive. The stock trades at $99.61 with a market cap of $12.15 billion. Earnings are scheduled for April 30, 2026. This maintained stance suggests confidence in the company’s long-term fundamentals despite recent headwinds.

Jefferies Maintains Buy on CLX Despite Price Target Cut

Analyst Action and Rating

Jefferies kept its Buy rating on Clorox intact while trimming its price target to $139 from $151. This represents a 7.9% reduction in the firm’s valuation estimate. The maintained rating signals that analysts still see upside potential, even as near-term challenges emerge. Jefferies lowered the price target citing near-term pressures, though the underlying thesis remains positive. The stock currently trades below both targets, suggesting room for recovery if the company executes well.

Market Context

Clorox shares have declined 2.51% in one day and 28.15% over the past year. The stock sits at $99.61, well below the 52-week high of $143.96. Trading volume reached 2.99 million shares, above the 30-day average of 2.23 million. This elevated activity reflects investor interest in the analyst action and broader market sentiment toward consumer defensive stocks.

Clorox Analyst Rating Consensus and Meyka Grade

Analyst Consensus Overview

The broader analyst community shows mixed sentiment on CLX. Among 14 tracked analysts, 2 rate Buy, 8 rate Hold, and 4 rate Sell. The consensus leans toward Hold (2.0 rating), indicating caution despite Jefferies’ optimism. This divergence suggests investors should weigh the firm’s constructive view against the more cautious majority. Meyka AI tracks CLX analyst coverage in real-time, capturing all rating changes and price targets.

Meyka AI Grade

Meyka AI rates CLX with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score of 75.99 reflects solid fundamentals balanced against valuation concerns. These grades are not guaranteed and we are not financial advisors.

Financial Metrics and Valuation

Key Financial Ratios

Clorox trades at a P/E ratio of 16.1, reasonable for a consumer defensive stock. The dividend yield stands at 2.47%, attractive for income-focused investors. Free cash flow per share totals $6.40, supporting the $2.48 dividend per share. Return on equity reaches 15.02%, indicating solid profitability. The company maintains an interest coverage ratio of 9.66x, showing strong debt servicing ability.

Growth and Profitability

Net profit margin sits at 11.17%, while operating margin reaches 15.15%. Revenue per share totals $55.57, with earnings per share at $6.11. The company generated $8.09 in operating cash flow per share over the trailing twelve months. These metrics demonstrate Clorox’s ability to generate consistent returns despite competitive pressures in household and personal products.

Sector Performance and Industry Dynamics

Consumer Defensive Positioning

Clorox operates in the Consumer Defensive sector within the Household & Personal Products industry. This defensive positioning typically provides stability during economic downturns. The company’s portfolio spans cleaning products, cat litter, food dressings, personal care, and water filtration. Brands include Clorox, Pine-Sol, Glad, Burt’s Bees, and Brita, providing diversification across consumer categories.

Market Challenges

The company faces pricing pressure and input cost inflation typical of the sector. Consumer spending patterns have shifted post-pandemic, affecting demand for certain product categories. Competition from private label brands and e-commerce disruption continue to pressure margins. Jefferies’ price target reduction reflects these structural headwinds, though the maintained Buy rating suggests management can navigate these challenges effectively.

Technical Indicators and Price Action

Momentum and Trend Signals

The RSI at 37.36 suggests oversold conditions, potentially indicating a bounce opportunity. The MACD histogram at 0.16 shows slight positive momentum, though the signal line remains negative. The Awesome Oscillator at -4.01 reflects bearish sentiment. The CCI at -161.86 indicates extreme oversold conditions, historically preceding reversals.

Volatility and Support Levels

Bollinger Bands show the stock trading near the lower band at $100.03, with the middle band at $103.48. The ATR of 3.34 indicates moderate volatility. The 50-day moving average sits at $112.74, providing resistance above current levels. The 200-day average at $114.56 represents longer-term resistance. Technical oversold conditions combined with analyst support suggest potential for mean reversion.

Earnings and Forward Outlook

Upcoming Earnings Report

Clorox will report earnings on April 30, 2026, after market close. This timing is critical for validating or challenging Jefferies’ maintained Buy thesis. Investors will focus on revenue trends, margin performance, and management guidance. The company’s ability to maintain pricing power while managing costs will determine near-term stock direction.

Forecast and Valuation

Meyka AI’s price forecasts suggest $116.76 for the next 12 months, implying 17.2% upside from current levels. The three-year forecast of $98.69 reflects near-term pressure before stabilization. These forecasts incorporate analyst consensus, technical patterns, and fundamental growth trends. The gap between current price and Jefferies’ $139 target suggests meaningful recovery potential if execution improves.

Final Thoughts

Jefferies’ maintained Buy rating on Clorox reflects confidence in the company’s long-term value despite near-term headwinds. The $139 price target, while reduced from $151, still implies 39.6% upside from current levels. The Clorox analyst rating consensus remains cautious, with more analysts favoring Hold than Buy, suggesting investors should monitor upcoming earnings closely. Meyka AI’s B+ grade indicates solid fundamentals, though valuation concerns persist. The stock’s technical oversold conditions combined with analyst support create a potential inflection point. Earnings on April 30 will be pivotal for confirming whether management can stabilize margins and justify the maintained optimism. For income investors, the 2.47% dividend yield provides downside support. The divergence between Jefferies’ bullish stance and the broader Hold consensus warrants careful consideration before making investment decisions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.